| Edoxaban versus warfarin in patients with atrial fibrillation RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ... New England Journal of Medicine 369 (22), 2093-2104, 2013 | 5791 | 2013 |
| Evolocumab and clinical outcomes in patients with cardiovascular disease MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ... New England journal of medicine 376 (18), 1713-1722, 2017 | 5555 | 2017 |
| Telmisartan, ramipril, or both in patients at high risk for vascular events Ontarget Investigators New England Journal of Medicine 358 (15), 1547-1559, 2008 | 4860 | 2008 |
| Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study K Swedberg, M Komajda, M Böhm, JS Borer, I Ford, A Dubost-Brama, ... The Lancet 376 (9744), 875-885, 2010 | 3316 | 2010 |
| Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) MD Flather, MC Shibata, AJS Coats, DJ Van Veldhuisen, A Parkhomenko, ... European heart journal 26 (3), 215-225, 2005 | 2293 | 2005 |
| Long-term use of ticagrelor in patients with prior myocardial infarction MP Bonaca, DL Bhatt, M Cohen, PG Steg, RF Storey, EC Jensen, ... New England Journal of Medicine 372 (19), 1791-1800, 2015 | 2132 | 2015 |
| Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes RR Holman, MA Bethel, RJ Mentz, VP Thompson, Y Lokhnygina, JB Buse, ... New England Journal of Medicine 377 (13), 1228-1239, 2017 | 1935 | 2017 |
| Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes H Haller, S Ito, JL Izzo Jr, A Januszewicz, S Katayama, J Menne, ... New England Journal of Medicine 364 (10), 907-917, 2011 | 1076 | 2011 |
| Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ... Jama 321 (1), 69-79, 2019 | 1071 | 2019 |
| Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors MR Weir, GL Bakris, DA Bushinsky, MR Mayo, D Garza, Y Stasiv, J Wittes, ... New England Journal of Medicine 372 (3), 211-221, 2015 | 677 | 2015 |
| Ivabradine in stable coronary artery disease without clinical heart failure K Fox, I Ford, PG Steg, JC Tardif, M Tendera, R Ferrari New England Journal of Medicine 371 (12), 1091-1099, 2014 | 618 | 2014 |
| EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study KK Ray, B Molemans, WM Schoonen, P Giovas, S Bray, G Kiru, J Murphy, ... European journal of preventive cardiology 28 (11), 1279-1289, 2021 | 536 | 2021 |
| Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized … M Jadzinsky, A Pfützner, E Paz‐Pacheco, Z Xu, E Allen, R Chen, ... Diabetes, Obesity and Metabolism 11 (6), 611-622, 2009 | 394 | 2009 |
| FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia DE Low, TM File Jr, PB Eckburg, GH Talbot, H David Friedland, J Lee, ... Journal of antimicrobial chemotherapy 66 (suppl_3), iii33-iii44, 2011 | 215 | 2011 |
| Cause of death and predictors of all‐cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF SD Pokorney, JP Piccini, SR Stevens, MR Patel, KS Pieper, JL Halperin, ... Journal of the American Heart Association 5 (3), e002197, 2016 | 154 | 2016 |
| REDUCE-IT USA: results from the 3146 patients randomized in the United States DL Bhatt, M Miller, EA Brinton, TA Jacobson, PG Steg, SB Ketchum, ... Circulation 141 (5), 367-375, 2020 | 133 | 2020 |
| The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction–baseline characteristics of the … VM Maria da Consolação, S Heringer-Walther, N Wessel, TM Ventura, ... Cardiology 110 (4), 271-282, 2008 | 89 | 2008 |
| Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry JP Bassand, S Virdone, SZ Goldhaber, AJ Camm, DA Fitzmaurice, ... Circulation 139 (6), 787-798, 2019 | 86* | 2019 |
| Angina and future cardiovascular events in stable patients with coronary artery disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry A Eisen, DL Bhatt, PG Steg, KA Eagle, S Goto, J Guo, SC Smith, ... Journal of the American Heart Association 5 (10), e004080, 2016 | 80 | 2016 |
| Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial MP Schlaich, M Bellet, MA Weber, P Danaietash, GL Bakris, JM Flack, ... The Lancet 400 (10367), 1927-1937, 2022 | 67 | 2022 |
Екатерина Лазиди; Lazidi KГУ "Национальный институт терапии им.Л.Т.Малой Национальной Академии Медицинских Наук Украины"Підтверджена електронна адреса в amnu.gov.ua
